Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

pectations, and we are looking forward to taking the next steps toward bringing it to market for patients who need to improve their cholesterol levels. Our next step for the routine high cholesterol population is to conduct a longer-term Phase 2 study in patients in combination with statins, in which we expect to use induction doses of 200 to 300 mg/week and define maintenance doses in the range of 100 to 200 mg/week."

ISIS 301012 Coadministered with Statins

This randomized, double-blinded, placebo-controlled, dose-escalation study initially included five weeks of treatment at doses of 30, 100, 200, and 300 mg/week. Because ISIS 301012 was well tolerated in these cohorts, the study was expanded to include a 400 mg/week five-week treatment group and two longer-term treatment cohorts; results of dose cohorts through 300 mg/week were presented previously, results from the 400 mg/week cohort were presented today, and results from the longer-term cohorts will be presented later in the year. Patients in the five-week study had median baseline LDL-C levels between 107 and 168 mg/dL and had been on stable doses of < / = 40 mg of simvastatin or atorvastatin for at least three months, with a median statin treatment duration of 4 years. At a dose of 400 mg/week, patients receiving ISIS 301012 achieved median reductions of 51% in apoB, 47% in LDL-C, and 35% in TG beyond the levels they had already achieved on stable statin doses. ISIS 301012 treatment had no effect on HDL-cholesterol levels (HDL-C).

Interestingly, in this short-term study, increasing the dose from 300 mg/week to 400 mg/week did not result in further lipid lowering activity represented as median % changes from baselines. This apparent plateau in % reductions may be due to the higher baseline values in the 300 mg/week cohort relative to the 400 mg/week cohort. Indeed, the 400 mg/week cohort did achieve lower median absolute levels of both apoB (55 mg/dL at 400 mg/week versus 61 mg/dL at 300 m
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/15/2014)... -- MedicOne Medical Response, a leading provider emergency ... by Inc. Magazine as one of the fastest ... Photo - http://photos.prnewswire.com/prnh/20140914/145997 ... companies with the largest revenue growth between 2010 ... two ambulance companies to make the list, achieved ...
(Date:9/15/2014)...  Catalist-listed QT Vascular Ltd. ("QT Vascular" or together ... of minimally invasive medical devices for the treatment of ... has enrolled the first European patients in the ENDURE ... have already been enrolled in this study with Dr. ... Auckland, New Zealand . ...
(Date:9/15/2014)... , Sept. 15, 2014  Over 200 patients, ... roof Saturday to learn, interact and participate in ... City,s first Lupus Trials Fair launched by the ... S.L.E. Lupus Foundation .  Attendees interacted directly ... -- sharing experiences, ideas and needs and learning ...
Breaking Medicine Technology:MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3
... ROCHESTER, N.Y., Sept. 8 VirtualScopics, Inc. (Nasdaq: ... for clinical trials, announced today that Ms. Molly Henderson, ... presenting a corporate overview at the Rodman & Renshaw ... City. Ms. Henderson,s presentation will be on Tuesday, September ...
... N.J., Sept. 8 Today every major pharmaceutical industry ... the future of pharma.  In an unprecedented move, they,re ... the big names in pharma.  All in one place. ... at the Pharma CI Conference & Exhibition at the ...
Cached Medicine Technology:VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference 2Pharmaceutical Industry Insiders, VIPs All Coming Together for Future of Pharma Market, Pharmaceutical Competitive Intelligence 2
(Date:9/15/2014)... York (PRWEB) September 15, 2014 Transvaginal ... Inc. continue to move forward in the federal multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... Final Order on September 10th that provides for the ... notes that none of the affected plaintiffs has objected ...
(Date:9/15/2014)... MONDAY, Sept. 15, 2014 (HealthDay News) -- U.S. heart ... an electrocardiogram (ECG) when evaluating young people for underlying ... The American Heart Association and the American College ... more detailed personal and family medical history along with ... genetic or congenital (existing from birth) risks for sudden ...
(Date:9/15/2014)... the prospective Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer ... affecting both the front and the crown of their ... risk of developing aggressive prostate cancer (usually indicates a ... non-aggressive prostate cancer) later in life, compared to men ... other patterns of baldness and prostate cancer risk. The ...
(Date:9/15/2014)... 2014 - An estimated 8% of Americans will suffer ... during their lifetime. Brought on by an overwhelming or ... altered chemistry and physiology of the brain. Understanding how ... altered by PTSD is essential to developing effective interventions. ... at The University of Texas at Dallas published online ...
(Date:9/15/2014)... FL (PRWEB) September 15, 2014 The ... away from putting low-level offenders in jail and prison ... Group sees this shift as a positive change. , ... prescription drug and heroin abuse. According to an ... parties are calling for a shift away from using ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:Certain form of baldness at age 45 linked to higher risk of aggressive prostate cancer 2Health News:EEG study findings reveal how fear is processed in the brain 2Health News:White House Shifts Policy on Drugs 2
... body of basic animal research and studies of abused ... for the hypothesis that individuals with particular genotypes are ... with the abuse of alcohol and other substances. ... assume that these genotypes identify people who are predestined ...
... Board of Directors Audit Committee Members and Complies with ... BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... J. Wilson as vice president of finance and principal ... team. She brings over twenty years of finance ...
... of Suntan Lotions, Reducing Risk of Deadly Skin Cancer ... & Prevention MonthNEW YORK, April 29 The ... people avoid overexposure to harmful ultraviolet radiation from the ... all across America reduce the risk of skin cancer ...
... 23-month-old child in Texas; CDC warns more deaths are ... 23-month-old child in Texas has become the first U.S. ... officials said Wednesday morning. , Dr. Richard Besser, acting ... Prevention, confirmed the death. No other details on the ...
... Dr. Gordon Norman presents overview of US healthcare ... Federation of Health Plans Meeting in Boston- Noted ... value for its healthcare investment- Emphasized greater coordination ... resolve today,s healthcare challenges MARIETTA, Ga., April 29 ...
... & Mentally IllNEW YORK, April 29 May marks ... it, philanthropic-minded New Yorkers will raise money for Weston ... and physically disabled. As federal and state funding ... the current economy, supporters will raise funds amidst live ...
Cached Medicine News:Health News:Genetic risk for anxiety does not have to be destiny 2Health News:PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 3Health News:U.S. Reports First Swine Flu Death 2Health News:U.S. Reports First Swine Flu Death 3Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 2Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 3Health News:Weston United Celebrates Mental Health Month on May 19th 2
... The Driver Stent design, utilizing ... the limitations of stainless steel ... possible thinner struts, for unparalleled ... The Driver Coronary Stent Systemwith ...
... Guiding Catheter provides support to enhance ... under adverse conditions. It gives you ... to your destination in cardiac interventions. ... variety of clinical situations and the ...
... Catheters are intended for use ... applications. They provide a pathway ... as balloon dilatation catheters, guide ... may be introduced. These devices ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
Medicine Products: